APO Research
Talk to an analyst

APO RESEARCH · REPORT

Female Contraception Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Female Contraception Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025189 pages

Choose your research edition.

Industry ResearchFemale Contraception Drug Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Female Contraception Drug Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Female Contraception Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Female Contraception Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Female Contraception Drug Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Female Contraception Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Female Contraception Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Female Contraception Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Female Contraception Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Female Contraception Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Female Contraception Drug include Teva Pharmaceutical Industries Ltd, Bayer AG, Viramal Ltd, Orbis Biosciences Inc, Mithra Pharmaceuticals SA, Hervana Ltd, Evofem Inc, Agile Therapeutics Inc and Addex Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Female Contraception Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Female Contraception Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Female Contraception Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Female Contraception Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Female Contraception Drug Segment by Company

Teva Pharmaceutical Industries Ltd

Bayer AG

Viramal Ltd

Orbis Biosciences Inc

Mithra Pharmaceuticals SA

Hervana Ltd

Evofem Inc

Agile Therapeutics Inc

Addex Therapeutics Ltd

Female Contraception Drug Segment by Type

AG-890

Drospirenone

BAY-1007626

Amphora

Others

Female Contraception Drug Segment by Application

Homecare

Hospital

Clinic

Female Contraception Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Female Contraception Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Female Contraception Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Female Contraception Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Female Contraception Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Female Contraception Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Female Contraception Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Female Contraception Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Female Contraception Drug Industry Trends Table 2. Female Contraception Drug Industry Drivers Table 3. Female Contraception Drug Industry Opportunities and Challenges Table 4. Female Contraception Drug Industry Restraints Table 5. Global Female Contraception Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Female Contraception Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Female Contraception Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Female Contraception Drug Sales Market Share by Manufacturers Table 9. Global Female Contraception Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Female Contraception Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Female Contraception Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Female Contraception Drug Manufacturers, Product Type & Application Table 13. Global Female Contraception Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Female Contraception Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of AG-890 Table 17. Major Manufacturers of Drospirenone Table 18. Major Manufacturers of BAY-1007626 Table 19. Major Manufacturers of Amphora Table 20. Major Manufacturers of Others Table 21. Global Female Contraception Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Female Contraception Drug Sales by Type (2021-2026) & (W Units) Table 23. Global Female Contraception Drug Sales by Type (2027-2032) & (W Units) Table 24. Global Female Contraception Drug Sales Market Share by Type (2021-2026) Table 25. Global Female Contraception Drug Sales Market Share by Type (2027-2032) Table 26. Global Female Contraception Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 27. Global Female Contraception Drug Revenue by Type (2021-2026) & (W Units) Table 28. Global Female Contraception Drug Revenue by Type (2027-2032) & (W Units) Table 29. Global Female Contraception Drug Revenue Market Share by Type (2021-2026) Table 30. Global Female Contraception Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Homecare Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Global Female Contraception Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Female Contraception Drug Sales by Application (2021-2026) & (W Units) Table 36. Global Female Contraception Drug Sales by Application (2027-2032) & (W Units) Table 37. Global Female Contraception Drug Sales Market Share by Application (2021-2026) Table 38. Global Female Contraception Drug Sales Market Share by Application (2027-2032) Table 39. Global Female Contraception Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 40. Global Female Contraception Drug Revenue by Application (2021-2026) & (W Units) Table 41. Global Female Contraception Drug Revenue by Application (2027-2032) & (W Units) Table 42. Global Female Contraception Drug Revenue Market Share by Application (2021-2026) Table 43. Global Female Contraception Drug Revenue Market Share by Application (2027-2032) Table 44. Global Female Contraception Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Female Contraception Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Female Contraception Drug Sales Market Share by Region (2021-2026) Table 47. Global Female Contraception Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 48. Global Female Contraception Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 50. North America Female Contraception Drug Sales by Country (2021-2026) & (W Units) Table 51. North America Female Contraception Drug Sales by Country (2027-2032) & (W Units) Table 52. Europe Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 53. Europe Female Contraception Drug Sales by Country (2021-2026) & (W Units) Table 54. Europe Female Contraception Drug Sales by Country (2027-2032) & (W Units) Table 55. Asia Pacific Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 56. Asia Pacific Female Contraception Drug Sales by Country (2021-2026) & (W Units) Table 57. Asia Pacific Female Contraception Drug Sales by Country (2027-2032) & (W Units) Table 58. South America, Middle East and Africa Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 59. South America, Middle East and Africa Female Contraception Drug Sales by Country (2021-2026) & (W Units) Table 60. South America, Middle East and Africa Female Contraception Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Female Contraception Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Female Contraception Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Female Contraception Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Female Contraception Drug Revenue Market Share by Region (2021-2026) Table 65. Global Female Contraception Drug Revenue Market Share by Region (2027-2032) Table 66. Teva Pharmaceutical Industries Ltd Company Information Table 67. Teva Pharmaceutical Industries Ltd Business Overview Table 68. Teva Pharmaceutical Industries Ltd Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Teva Pharmaceutical Industries Ltd Female Contraception Drug Product Portfolio Table 70. Teva Pharmaceutical Industries Ltd Recent Development Table 71. Bayer AG Company Information Table 72. Bayer AG Business Overview Table 73. Bayer AG Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bayer AG Female Contraception Drug Product Portfolio Table 75. Bayer AG Recent Development Table 76. Viramal Ltd Company Information Table 77. Viramal Ltd Business Overview Table 78. Viramal Ltd Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Viramal Ltd Female Contraception Drug Product Portfolio Table 80. Viramal Ltd Recent Development Table 81. Orbis Biosciences Inc Company Information Table 82. Orbis Biosciences Inc Business Overview Table 83. Orbis Biosciences Inc Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Orbis Biosciences Inc Female Contraception Drug Product Portfolio Table 85. Orbis Biosciences Inc Recent Development Table 86. Mithra Pharmaceuticals SA Company Information Table 87. Mithra Pharmaceuticals SA Business Overview Table 88. Mithra Pharmaceuticals SA Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Mithra Pharmaceuticals SA Female Contraception Drug Product Portfolio Table 90. Mithra Pharmaceuticals SA Recent Development Table 91. Hervana Ltd Company Information Table 92. Hervana Ltd Business Overview Table 93. Hervana Ltd Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Hervana Ltd Female Contraception Drug Product Portfolio Table 95. Hervana Ltd Recent Development Table 96. Evofem Inc Company Information Table 97. Evofem Inc Business Overview Table 98. Evofem Inc Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Evofem Inc Female Contraception Drug Product Portfolio Table 100. Evofem Inc Recent Development Table 101. Agile Therapeutics Inc Company Information Table 102. Agile Therapeutics Inc Business Overview Table 103. Agile Therapeutics Inc Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Agile Therapeutics Inc Female Contraception Drug Product Portfolio Table 105. Agile Therapeutics Inc Recent Development Table 106. Addex Therapeutics Ltd Company Information Table 107. Addex Therapeutics Ltd Business Overview Table 108. Addex Therapeutics Ltd Female Contraception Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Addex Therapeutics Ltd Female Contraception Drug Product Portfolio Table 110. Addex Therapeutics Ltd Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Female Contraception Drug Distributors List Table 114. Female Contraception Drug Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Female Contraception Drug Product Image Figure 2. Global Female Contraception Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Female Contraception Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Female Contraception Drug Sales (2021-2032) & (W Units) Figure 5. Global Female Contraception Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Female Contraception Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. AG-890 Image Figure 9. Drospirenone Image Figure 10. BAY-1007626 Image Figure 11. Amphora Image Figure 12. Others Image Figure 13. Global Female Contraception Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Female Contraception Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Female Contraception Drug Sales Market Share by Type (2021-2032) Figure 16. Global Female Contraception Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Female Contraception Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Female Contraception Drug Revenue Market Share by Type (2021-2032) Figure 19. Homecare Image Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Global Female Contraception Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Female Contraception Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Female Contraception Drug Sales Market Share by Application (2021-2032) Figure 25. Global Female Contraception Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 26. Global Female Contraception Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Female Contraception Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 29. North America Female Contraception Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Canada Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Mexico Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Female Contraception Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 36. France Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. U.K. Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Italy Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Netherlands Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Female Contraception Drug Sales Market Share by Country (2021-2032) Figure 42. China Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Japan Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. South Korea Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Southeast Asia Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. India Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Australia Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Female Contraception Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 51. South Africa Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Saudi Arabia Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Turkey Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Argentina Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. UAE Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Egypt Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Chile Female Contraception Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Global Female Contraception Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Female Contraception Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Female Contraception Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Female Contraception Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Female Contraception Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Female Contraception Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Female Contraception Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Female Contraception Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • AG-890
  • Drospirenone
  • BAY-1007626
  • Amphora
  • Others
Applications
  • Homecare
  • Hospital
  • Clinic
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Bayer AG
  • Viramal Ltd
  • Orbis Biosciences Inc
  • Mithra Pharmaceuticals SA
  • Hervana Ltd
  • Evofem Inc
  • Agile Therapeutics Inc
  • Addex Therapeutics Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Female Contraception Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Female Contraception Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Female Contraception Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Female Contraception Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Female Contraception Drug Market Dynamics
  1. 2.1 Female Contraception Drug Industry Trends
  2. 2.2 Female Contraception Drug Industry Drivers
  3. 2.3 Female Contraception Drug Industry Opportunities and Challenges
  4. 2.4 Female Contraception Drug Industry Restraints
3 Female Contraception Drug Market by Manufacturers
  1. 3.1 Global Female Contraception Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Female Contraception Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Female Contraception Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Female Contraception Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Female Contraception Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Female Contraception Drug Manufacturers, Product Type & Application
  7. 3.7 Global Female Contraception Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Female Contraception Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Female Contraception Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Female Contraception Drug Tier 1, Tier 2, and Tier 3
4 Female Contraception Drug Market by Type
  1. 4.1 Female Contraception Drug Type Introduction
  2. 4.1.1 AG-890
  3. 4.1.2 Drospirenone
  4. 4.1.3 BAY-1007626
  5. 4.1.4 Amphora
  6. 4.1.5 Others
  7. 4.2 Global Female Contraception Drug Sales by Type
  8. 4.2.1 Global Female Contraception Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Female Contraception Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Female Contraception Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Female Contraception Drug Revenue by Type
  12. 4.3.1 Global Female Contraception Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Female Contraception Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Female Contraception Drug Revenue Market Share by Type (2021-2032)
5 Female Contraception Drug Market by Application
  1. 5.1 Female Contraception Drug Application Introduction
  2. 5.1.1 Homecare
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.2 Global Female Contraception Drug Sales by Application
  6. 5.2.1 Global Female Contraception Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Female Contraception Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Female Contraception Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Female Contraception Drug Revenue by Application
  10. 5.3.1 Global Female Contraception Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Female Contraception Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Female Contraception Drug Revenue Market Share by Application (2021-2032)
6 Global Female Contraception Drug Sales by Region
  1. 6.1 Global Female Contraception Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Female Contraception Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Female Contraception Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Female Contraception Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Female Contraception Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Female Contraception Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Female Contraception Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Female Contraception Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Female Contraception Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Female Contraception Drug Revenue by Region
  1. 7.1 Global Female Contraception Drug Revenue by Region
  2. 7.1.1 Global Female Contraception Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Female Contraception Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Female Contraception Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Female Contraception Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Female Contraception Drug Revenue (2021-2032)
  8. 7.2.2 North America Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Female Contraception Drug Revenue (2021-2032)
  11. 7.3.2 Europe Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Female Contraception Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Female Contraception Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Female Contraception Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries Ltd
  2. 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Ltd Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Ltd Female Contraception Drug Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 8.2 Bayer AG
  8. 8.2.1 Bayer AG Company Information
  9. 8.2.2 Bayer AG Business Overview
  10. 8.2.3 Bayer AG Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG Female Contraception Drug Product Portfolio
  12. 8.2.5 Bayer AG Recent Developments
  13. 8.3 Viramal Ltd
  14. 8.3.1 Viramal Ltd Company Information
  15. 8.3.2 Viramal Ltd Business Overview
  16. 8.3.3 Viramal Ltd Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Viramal Ltd Female Contraception Drug Product Portfolio
  18. 8.3.5 Viramal Ltd Recent Developments
  19. 8.4 Orbis Biosciences Inc
  20. 8.4.1 Orbis Biosciences Inc Company Information
  21. 8.4.2 Orbis Biosciences Inc Business Overview
  22. 8.4.3 Orbis Biosciences Inc Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Orbis Biosciences Inc Female Contraception Drug Product Portfolio
  24. 8.4.5 Orbis Biosciences Inc Recent Developments
  25. 8.5 Mithra Pharmaceuticals SA
  26. 8.5.1 Mithra Pharmaceuticals SA Company Information
  27. 8.5.2 Mithra Pharmaceuticals SA Business Overview
  28. 8.5.3 Mithra Pharmaceuticals SA Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Mithra Pharmaceuticals SA Female Contraception Drug Product Portfolio
  30. 8.5.5 Mithra Pharmaceuticals SA Recent Developments
  31. 8.6 Hervana Ltd
  32. 8.6.1 Hervana Ltd Company Information
  33. 8.6.2 Hervana Ltd Business Overview
  34. 8.6.3 Hervana Ltd Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hervana Ltd Female Contraception Drug Product Portfolio
  36. 8.6.5 Hervana Ltd Recent Developments
  37. 8.7 Evofem Inc
  38. 8.7.1 Evofem Inc Company Information
  39. 8.7.2 Evofem Inc Business Overview
  40. 8.7.3 Evofem Inc Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Evofem Inc Female Contraception Drug Product Portfolio
  42. 8.7.5 Evofem Inc Recent Developments
  43. 8.8 Agile Therapeutics Inc
  44. 8.8.1 Agile Therapeutics Inc Company Information
  45. 8.8.2 Agile Therapeutics Inc Business Overview
  46. 8.8.3 Agile Therapeutics Inc Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Agile Therapeutics Inc Female Contraception Drug Product Portfolio
  48. 8.8.5 Agile Therapeutics Inc Recent Developments
  49. 8.9 Addex Therapeutics Ltd
  50. 8.9.1 Addex Therapeutics Ltd Company Information
  51. 8.9.2 Addex Therapeutics Ltd Business Overview
  52. 8.9.3 Addex Therapeutics Ltd Female Contraception Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Addex Therapeutics Ltd Female Contraception Drug Product Portfolio
  54. 8.9.5 Addex Therapeutics Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Female Contraception Drug Value Chain Analysis
  2. 9.1.1 Female Contraception Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Female Contraception Drug Production Mode & Process
  6. 9.2 Female Contraception Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Female Contraception Drug Distributors
  9. 9.2.3 Female Contraception Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst